In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to ...
FDA label expansion adds relapse-prevention in adult schizophrenia, addressing a major driver of hospitalization, functional ...
Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...
Gen2X enhances the RAIN RFID protocol with faster inventories, improved sensitivity/range, tighter read-zone confinement, and ...
While the goal is to reduce the cost burden on US patients, many in the industry are warning that there could be consequences ...
Increasingly complex cell therapy modalities, including multi-edit knock-in/knockout designs, are accelerating adoption of ...
The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
AbbVie received a Complete Response Letter (CRL) from the FDA for its Biologics License Application (BLA) for ...
The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...
FDA is formalizing RWD as core evidence, enabling “single pivotal trial plus confirmatory evidence” approaches that may ...
Radiopharmaceutical pipelines are broadening beyond prostate cancer into multitumor programs, pairing alpha/beta emitters with immunotherapy or DDR agents and driving investments in isotope supply, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results